<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046214</url>
  </required_header>
  <id_info>
    <org_study_id>2008-1668</org_study_id>
    <nct_id>NCT01046214</nct_id>
  </id_info>
  <brief_title>Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions</brief_title>
  <official_title>A Multiple-Dose, Double Blind, Double Dummy, Comparative Bioavailability Study of Two Formulations of Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the comparative bioavailability between bupropion&#xD;
      hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL®&#xD;
      300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment issues&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative bioavailability</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Budeprion XL™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wellbutrin XL®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion HCl</intervention_name>
    <description>Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet</description>
    <arm_group_label>Budeprion XL™</arm_group_label>
    <other_name>Budeprion XL™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion HCl</intervention_name>
    <description>Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet</description>
    <arm_group_label>Wellbutrin XL®</arm_group_label>
    <other_name>Wellbutrin XL®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, 25 years of age or older&#xD;
&#xD;
          -  Diagnosis of any depressive disorder as per DSM IV criteria (except bipolar depression&#xD;
             and major depressive disorder with psychotic features). Note: Both patients who are or&#xD;
             are not being treated with bupropion or other antidepressants are permitted into the&#xD;
             study.&#xD;
&#xD;
          -  Patients must have complained of suffering from adverse events and/or lack of effect&#xD;
             when switched from Wellbutrin XL® 300 mg to Budeprion XL™ 300 mg.&#xD;
&#xD;
          -  BMI (kg/m2) Greater than or equal to 19 and less than or equal to 34.&#xD;
&#xD;
          -  No clinically significant abnormal laboratory values&#xD;
&#xD;
          -  No clinically significant findings in a 12-lead electrocardiogram (ECG)&#xD;
&#xD;
          -  No clinically significant findings in vital signs measurements.&#xD;
&#xD;
          -  Be informed of the nature of the study and give written consent prior to receiving any&#xD;
             study procedure.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Carcinoma within the last 5 years. Note: Patients with basal or squamous cell&#xD;
             carcinoma may be permitted into the study on a case by case basis.&#xD;
&#xD;
          -  A history of epilepsy or risk for seizures.&#xD;
&#xD;
          -  A previous or current diagnosis of bipolar depression.&#xD;
&#xD;
          -  A current diagnosis of major depressive episode with psychotic features. Note:&#xD;
             Subjects with previous diagnosis of major depressive episode with psychotic features&#xD;
             may be included at the investigator's discretion.&#xD;
&#xD;
          -  A previous or current diagnosis of an eating disorder (e.g. bulimia, anorexia&#xD;
             nervosa).&#xD;
&#xD;
          -  A lifetime history of schizophrenia or schizo-affective disorder.&#xD;
&#xD;
          -  Significant disease(s) or clinically significant finding(s) in a physical examination&#xD;
             determined by an investigator to pose a health concern to the patient while on study.&#xD;
&#xD;
          -  Presence of clinically significant gastrointestinal disease and/or surgery (e.g.&#xD;
             gastric bypass surgery) or history of malabsorption within the last year.&#xD;
&#xD;
          -  Known history or presence of an allergic sensitivity to bupropion and/or any other&#xD;
             drug substances with similar activity.&#xD;
&#xD;
          -  Expected changes in use of permitted concomitant medication that will be continued&#xD;
             throughout the study.&#xD;
&#xD;
          -  Undergoing abrupt discontinuation of sedatives (including benzodiazepines).&#xD;
&#xD;
          -  Use of monoamine oxidase inhibitors (MAOI) within 2 weeks prior to study admission.&#xD;
&#xD;
          -  Taking medications that interact with CYP2B6 within 30 days prior to Day 1 dosing.&#xD;
&#xD;
          -  Taking levodopa, amantadine, drugs that lower seizure threshold (e.g. theophylline,&#xD;
             systemic steroids, antipsychotics), and/or on nicotine replacement therapy.&#xD;
&#xD;
          -  History of alcohol or drug-dependence by DSM IV criteria within 6 months prior to&#xD;
             study admission.&#xD;
&#xD;
          -  Positive test results for:&#xD;
&#xD;
               -  HIV&#xD;
&#xD;
               -  Hepatitis B surface antigen or Hepatitis C antibody&#xD;
&#xD;
               -  Urine drugs of abuse (i.e. marijuana, amphetamines, barbiturates, cocaine,&#xD;
                  opiates, methadone, and phencyclidine) Note: any positive test result(s) for&#xD;
                  benzodiazepine(s) must be assessed by the investigator to determine whether the&#xD;
                  patient should be excluded from this study.&#xD;
&#xD;
               -  Serum hCG consistent with pregnancy (females only).&#xD;
&#xD;
          -  On a special diet within 30 days prior to study admission (e.g. liquid, protein, raw&#xD;
             food diet).&#xD;
&#xD;
          -  Difficulty fasting or consuming standard meals.&#xD;
&#xD;
          -  Participated in another clinical trial or received an investigational product within&#xD;
             45 days prior to Day 1 drug administration.&#xD;
&#xD;
          -  Donation or loss of whole blood:&#xD;
&#xD;
               -  Less than or equal to 499 mL within 30 days prior to dosing&#xD;
&#xD;
               -  Greater than or equal to 500 mL within 56 days prior to dosing Note: blood taken&#xD;
                  for routine medical evaluations totaling less than 50 mL will be permitted.&#xD;
&#xD;
          -  Females who have discontinued the use of:&#xD;
&#xD;
               -  implanted, intrauterine, or injected hormonal contraceptives within 6 months&#xD;
                  prior to Day 1 drug administration, OR&#xD;
&#xD;
               -  oral, intravaginal, or patch hormonal contraceptives within 1 month prior to Day&#xD;
                  1 drug administration&#xD;
&#xD;
          -  Females who started taking:&#xD;
&#xD;
               -  implanted or intrauterine hormonal contraceptives less than 6 months prior to Day&#xD;
                  1 drug administration, OR&#xD;
&#xD;
               -  oral, intravaginal, patch, or injected hormonal contraceptives less than 3 months&#xD;
                  prior to Day 1 drug administration.&#xD;
&#xD;
          -  Females who are pregnant, lactating, or likely to become pregnant during the study.&#xD;
&#xD;
          -  Have had a newly applied tattoo or body piercing within 30 days prior to study&#xD;
             admission.&#xD;
&#xD;
          -  Does not tolerate venipuncture.&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lev Gertsik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

